NMT Medical, Inc. Assigned All Its Assets to Joseph F. Finn, Jr., C.P.A. of the Firm Finn, Warnke & Gayton, LLP on April 20, 2011

WELLESLEY HILLS, Mass., May 2, 2011 /PRNewswire/ — On April 20,
2011, NMT Medical, Inc. (“NMT Medical”) assigned all its assets to
Joseph F. Finn, Jr., C.P.A. (“Finn”) of the firm Finn, Warnke &
Gayton, LLP to be liquidated for the benefit of NMT Medical
creditors.

NMT Medical’s intellectual property consists of:

• CLOSURE I Clinical Trial Data;

• MIST and MIST II Clinical Trial Data;

• CardioSEAL®, STARFlex®, and BioSTAR® Technologies
  for Septal Defect Repair;

• BioTREK™ Bioabsorbable Technology for Intracardiac Defect
  Closure, and

• Alternative Technologies for Intracardiac  Defect
  Closure

The intellectual property, patents, etc. will be sold at a
sealed bid sale on Friday, June 10, 2011 at noon.  Persons
interested in bidding must sign a Confidentiality Disclosure
Agreement (“CDA”) obtained from Finn’s Office –
jffinnjr@finnwarnkegayton.com or 781-237-8840.  They will
then receive a bid package.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is a founding partner of the firm
Finn, Warnke & Gayton (www.finnwarnkegayton.com),
Certified Public Accountants of Wellesley Hills, Massachusetts.
 He works primarily in the area of management consulting for
distressed enterprises, bankruptcy accounting and related matters,
such as assignee for the benefit of creditors and liquidating agent
for a corporation.  He has been involved in a number of loan
workouts and bankruptcy cases for thirty-five (35) years.  His
most recent Assignments for the Benefit of Creditors in the biotech
field include Spherics, Inc., ActivBiot

‘/>”/>

SOURCE